Understanding the Market | GENFLEET-B turns from decline to rise of over 9%, first patient enrolled in the study of GFH375 combination therapy for advanced solid tumors completed
GENFLEET-B's stock price turned from decline to increase in the afternoon, with an increase of over 9%. As of the time of publication, the stock price rose by 6.71%, reported at HKD 28.3, with a trading volume of HKD 44.5183 million. The company announced that its KRAS G12D inhibitor GFH375 combination therapy has completed the enrollment of the first patient at Peking University Cancer Hospital, with the study approved by the National Medical Products Administration, involving combination with cetuximab or chemotherapy. The efficacy and safety of GFH375 will be reported at the 2025 ESMO Annual Meeting
According to the Zhitong Finance APP, GENFLEET-B (02595) fell more than 8% in the afternoon but surged over 9% near the close. As of the time of publication, it rose 6.71%, trading at HKD 28.3, with a transaction volume of HKD 44.5183 million.
In terms of news, GENFLEET announced that its oral high-potency and highly selective small molecule KRAS G12D (ON/OFF) inhibitor GFH375 is being used in a combined therapy for the treatment of KRAS G12D mutant advanced solid tumors in an Ib/II phase study, with the first patient enrolled at Peking University Cancer Hospital. This study received clinical trial approval from the National Medical Products Administration in September this year and involves two combination therapies with cetuximab or chemotherapy, with the GFH375 combined chemotherapy regimen being a first-line treatment for pancreatic ductal adenocarcinoma (PDAC).
It is noteworthy that data on GFH375 monotherapy for KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) patients was presented on October 19 at the 2025 ESMO Annual Meeting as a breakthrough research abstract (LBA) and oral report. The oral report was delivered by Professor Zhou Aiping from the Chinese Academy of Medical Sciences Cancer Hospital, titled "Efficacy and Safety of GFH375 in Treating Patients with Previously Treated Advanced KRAS G12D Mutant PDAC." The report focused on the study data of PDAC patients in the 600 mg QD (RP2D) dosage group, showing that GFH375 demonstrated outstanding efficacy and controllable safety in treating PDAC patients
